Emergent BioSolutions Inc.
EBSHealthcare|Drug Manufacturers - Specialty & Generic|US
$6.06
+0.21 (+3.59%)
DCF Value
$3.57
Tangible Book / Share
$1.18
Cash / Share
$3.42
Clinical Trials (65)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03220737 VAXCHORA Pediatric Study to Assess Safety and Immunogenicity | Cholera (Disorder) | P4 | Completed | 550 | RCT, Double-blind | VAXCHORA (Cholera Vaccine, Live, Oral) |
| NCT02051062 BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients | Botulism | P4 | By Invite | 10 | Open-label | Blood sample collection |
| NCT02339155 Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed | Infections, Bacterial | P4 | Completed | 573 | RCT, Open-label | AVA, Raxibacumab, Diphenhydramine |
| NCT02443623 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV | Smallpox Vaccine Adverse Reaction | P4 | Completed | 3,032 | Open-label | Vaccination with ACAM2000 |
| NCT02177721 Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario | Infections, Bacterial | P4 | Not Yet Recruiting | 100 | Open-label | Sample Collection |
| NCT00639678 A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects | Healthy | P3 | Completed | 322 | RCT, Single-blind | placebo, raxibacumab, placebo, raxibacumab |
| NCT02016963 An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection | Therapeutic Treatment of Inhalation Anthrax | P2P3 | Completed | 20 | Open-label | Raxibacumab |
| NCT05072080 A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) | Chikungunya Virus | P3 | Completed | 3,258 | RCT, Double-blind | CHIKV VLP/adjuvant, Placebo |
| NCT01158157 VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV | Smallpox Vaccine Adverse Reaction | P3 | Completed | 25 | Open-label | ACAM2000 |
| NCT03877926 VELOCITY: An Anthrax Vaccine Clinical Study | Anthrax | P3 | Completed | 3,689 | RCT, Double-blind | AV7909, BioThrax |
| NCT02094586 A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults | Cholera | P3 | Completed | 3,146 | RCT, Double-blind | PXVX0200 Lot A, PXVX0200 Lot B, PXVX0200 Lot C, Placebo |
| NCT02100631 A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults | Cholera | P3 | Completed | 398 | RCT, Double-blind | PXVX0200, Placebo |
| NCT05349617 Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years | Chikungunya Virus | P3 | Completed | 413 | RCT, Double-blind | CHIKV VLP/adjuvant, Placebo |
| NCT01895855 Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera | Cholera | P3 | Completed | 197 | RCT, Double-blind | PXVX0200, placebo |
| NCT01311674 Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) | Healthy Volunteers | P3 | Terminated | 141 | RCT, Open-label | hepatitis B vaccine, hepatitis B vaccine |
| NCT00877656 HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma | T Cell Lymphoma | P2P3 | Completed | 21 | RCT, Open-label | HuMax-CD4 |
| NCT01491607 Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults | Anthrax | P3 | Completed | 200 | Open-label | BioThrax |
| NCT00634933 Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis | Arthritis, Rheumatoid | P2 | Terminated | 222 | RCT, Double-blind | TRU-015, Methylprednisolone, Prednisone, TRU-015, Methylprednisolone, Prednisone, TRU-015, Methylprednisolone, Prednisone |
| NCT00845650 Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) | Anthrax | P1P2 | Completed | 129 | RCT, Double-blind | AIGIV 3.5 mg/kg, Gamunex 90 mg/kg, AIGIV 7.0 mg/kg, Gamunex 180 mg/kg, AIGIV 14.0 mg/kg, Gamunex 360 mg/kg |
| NCT00053495 Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination | Smallpox | P2 | Completed | 353 | RCT, Double-blind | Vaccinia virus: ACAM2000 smallpox vaccine, vaccinia virus (calf lymph): Dryvax |
| NCT04067011 Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study | Anthrax | P2 | Completed | 210 | RCT, Open-label | Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet, AV7909 |
| NCT03992872 Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) | Chikungunya | P2 | Completed | 60 | Open-label | Chikungunya |
| NCT02145377 PXVX0200 (CVD103-HgR) vs Shanchol in Mali | Cholera | P2 | Completed | 150 | RCT, Double-blind | PXVX0200 10E8, PXVX0200 10E9, Placebo, Shanchol |
| NCT01770743 A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels | Anthrax | P2 | Completed | 168 | RCT, Double-blind | AV7909, BioThrax |
| NCT03483961 Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults | Chikungunya Virus Infection | P2 | Completed | 445 | RCT, Double-blind | CHIKV VLP/unadjuvanted, CHIKV VLP/adjuvanted, Placebo |
| NCT01753115 Ciprofloxacin BioThrax Co-Administration Study | Anthrax | P2 | Completed | 154 | RCT, Open-label | BioThrax, Ciprofloxacin |
| NCT05065983 A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine | Chikungunya Virus | P2 | Completed | 25 | Open-label | CHIKV VLP, adjuvanted |
| NCT00679172 Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults | Typhoid | P2 | Completed | 187 | RCT, Double-blind | Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3), Dose of of 1.7 x 10^10 CFU (Cohort 4) |
| NCT03315104 Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A | Influenza A H3N2, Influenza A H1N1 | P2 | Completed | 65 | RCT, Double-blind | FLU-IGIV |
| NCT00053482 Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults | Smallpox | P2 | Completed | 357 | RCT, Double-blind | ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smallpox vaccine: Dryvax® |
| NCT00893516 CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma | T-cell Lymphoma | P2 | Terminated | 5 | RCT, Open-label | CHOP + CD4, CHOP |
| NCT02061358 Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects | Viral Infection | P1 | Completed | 64 | RCT, Double-blind | UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg, UV-4B 90 mg, UV-4B 180 mg, UV-4B 360 mg, UV-4B 720 mg, UV-4B 1000 mg, Placebo |
| NCT04661839 A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults | COVID-19 | P1 | Completed | 28 | RCT, Double-blind | COVID-HIGIV |
| NCT05935917 Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults | Smallpox | P1 | Completed | 44 | RCT, Open-label | Brincidofovir |
| NCT01006798 Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1 | Bird Flu, Influenza | P1 | Completed | 166 | RCT, Double-blind | Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1 |
| NCT05194358 Study of SIAN Nasal Spray in Healthy Adults | Cyanide Poisoning | P1 | Completed | 47 | Open-label | Stabilized Isoamyl Nitrite (SIAN) |
| NCT03624946 Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG) | Zika Virus Infection, Zika Virus Disease | P1 | Completed | 30 | RCT, Double-blind | Zika Virus Immune Globulin (ZIKV-IG) |
| NCT01989533 Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers | Vaccine Response | P1 | Completed | 62 | RCT, Double-blind | Ad4-mgag, Ad4-EnvC150, gp 120 Protein Boost |
| NCT01585181 Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 | Cholera | P1 | Completed | 66 | RCT, Double-blind | PXVX0200, Placebo |
| NCT05142306 A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults | SARS-CoV-2 Infection | P1 | Completed | 23 | RCT, Open-label | COVID-HIG |
| NCT01263691 Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults | Bacillus Anthracis (Anthrax) Infection | P1 | Completed | 105 | RCT, Double-blind | BioThrax, AV7909 Formulation 1, AV7909 Formulation 2, AV7909 Formulation 3, AV7909 Formulation 4, Control |
| NCT00360737 Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses | Healthy | P1 | Completed | 40 | RCT, Double-blind | Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE) |
| NCT03425149 Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults | Zika Virus, Zika Virus Infection | P1 | Completed | 67 | RCT, Double-blind | VLA1601, Placebo |
| NCT00636519 Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle | Healthy Volunteers | P1 | Completed | 36 | RCT, Double-blind | Botulism Antitoxin Bivalent (Equine) Types A and B, Botulism Antitoxin Heptavalent (Equine) Types A-G |
| NCT02696291 Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects | Viral Infection | P1 | Terminated | 7 | RCT, Double-blind | UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo |
| NCT05155319 Universal Influenza A Vaccine in Healthy Adults | Human Influenza | P1 | Completed | 27 | RCT, Double-blind | UFluA 20 µg each antigen/dose, UFluA 60 µg each antigen/dose, Placebo |
| NCT00448253 Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum | Symptoms of Inhalational Anthrax | P1 | Completed | 92 | RCT, Double-blind | NP-015 |
| NCT01202695 Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9) | Anthrax | P1 | Completed | 50 | RCT, Double-blind | AVP-21D9, Placebo |
| NCT05377255 Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults | Opioid Overdose | P1 | Completed | 24 | RCT, Open-label | — |
| NCT03160339 A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 | Adenoviral Infection | P1 | Terminated | 25 | RCT, Double-blind | PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine |
| NCT01979406 A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines | Anthrax Infection | P1 | Completed | 120 | RCT, Double-blind | AVA, Ad4-PA-1, Ad4-PA-GPI-1 |
| NCT02771730 Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults | Healthy Volunteer, HIV Vaccine | P1 | Terminated | 20 | RCT, Double-blind | Ad4-mgag, Ad4-EnvC150, AIDSVAX B/E |
| NCT01683773 Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A | Tuberculosis | P1 | Completed | 40 | Open-label | AERAS-402, MVA85A |
| NCT02055183 BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin | Botulism | Completed | 162 | — | BAT | |
| NCT01395082 ACAM2000® Myopericarditis Registry | Myocarditis, Pericarditis | Completed | 24 | — | — | |
| NCT01540929 Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel | Smallpox | Completed | 5,001 | — | — | |
| NCT00928577 Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®) | Smallpox | Completed | 14,108 | — | — | |
| NCT00927719 Safety Surveillance Study of ACAM2000® Vaccinia Vaccine | Smallpox | Completed | 897,227 | — | ACAM2000® smallpox vaccine | |
| NCT03569553 A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients | Inhalational Anthrax | Not Yet Recruiting | 100 | — | AIGIV | |
| NCT01374984 VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection | Complication of Smallpox Vaccination | By Invite | 100 | — | VIGIV | |
| NCT07268612 Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease. | Anthrax | Not Yet Recruiting | 250 | — | CYFENDUS | |
| NCT01653392 BioThrax® (Anthrax) Vaccine in Pregnancy Registry | Pregnancy Complications, Pregnancy Outcome | Completed | 98 | — | Observational Intervention | |
| NCT02391909 Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers | Typhoid Fever | Completed | 855 | — | Vivotif | |
| NCT03569514 Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax | Anthrax | Not Yet Recruiting | 10 | — | AIGIV | |
| NCT07478471 Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax | Infections, Bacterial | Not Yet Recruiting | 10 | — | Collection of samples |